Spots Global Cancer Trial Database for A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)

Official Title: An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Intratumor Injection Mediated GPC3-targeted Chimeric Antigen Receptor T Cells in Advanced Hepatocellular Carcinoma

Study ID: NCT03130712

Conditions

Carcinoma, Hepatocellular

Interventions

GPC3-CART cells

Study Description

Brief Summary: In this study, CART cells are targeted to GPC3 by intratumor injected that we hope by this means could improve the local CAR-T cell numbers, meanwhile reduce the potential side effects.

Detailed Description: Patients treated with leukapheresis to obtain peripheral blood mononuclear cells, and then PBMC are purified. T cells are activated and then re-engineered to express chimeric antigen receptors (CARs) specific for GPC3. Cells are expanded in culture and returned to the participant by intratumor injection at the dose of(1-10)×106 CAR positive T cells. The cells perfusion process would only last for (1-2) min. GPC-CART cells are injected into each tumor focus only once.